SCHEMBL1870100

SCHEMBL1870100

COc1[c]cc(N)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8717623 0.78
SCHEMBL28818310 0.76 TDP1 (0.31)
SCHEMBL105204 0.73 CA1 (0.48)
SCHEMBL160506 0.73
SCHEMBL19917 0.71
SCHEMBL21590 0.71
SCHEMBL340606 0.71
SCHEMBL194173 0.71
SCHEMBL161096 0.71
SCHEMBL28053489 0.71 CA1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984734-B1 SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS UNIV BARI (IT) 2014-05-07 EP claimed
US-20090017038-A1 Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods UNIVERSITA DEGLI STUDI DI BARI (IT) 2009-01-15 US claimed
EP-1984734-A2 SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS Universita' degli studi di Bari (IT) 2008-10-29 EP claimed
WO-2008073451-A2 BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC. (US) 2008-06-19 WO claimed
WO-2007077543-A2 SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS UNIVERSITA' DEGLI STUDI DI BARI (IT) 2007-07-12 WO claimed
CN-116425721-B Bicyclic compounds as MAT2A inhibitors 艾立康药业股份有限公司 2024-02-02 CN disclosed
CN-116425721-A Bicyclic compounds as MAT2A inhibitors 艾立康药业股份有限公司 2023-07-14 CN disclosed
CN-113444016-A Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 美国陶氏益农公司 2021-09-28 CN disclosed
CN-107734969-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 美国陶氏益农公司 2021-06-01 CN disclosed
CN-110913855-A Imidazole-containing ALK2 kinase inhibitors 拜奥克里斯特制药公司 2020-03-24 CN disclosed
CN-106458930-B 2-aminopyrimidine compound and pharmaceutical composition and application thereof 中国科学院上海药物研究所 2019-10-11 CN disclosed
CN-109690317-A For measuring the composition and method of cell intermediate ion channel activity 生命科技股份有限公司 2019-04-26 CN disclosed
WO-2008073451-A2 BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed
WO-2008016192-A2 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-07 WO disclosed
US-7094798-B1 Inhibitors of checkpoint kinases (Wee1 and Chk1) PFIZER INC (US) 2006-08-22 US disclosed
CN-1190197-C Application of cyanoquinoline in preparing medicine for treating or inhibiting colonic polyp HEWLETT HOLDINGS CORP (US) 2005-02-23 CN disclosed
EP-1501831-A1 INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) WARNER-LAMBERT COMPANY LLC (US) 2005-02-02 EP disclosed
WO-2003091255-A1 INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) WARNER-LAMBERT COMPANY LLC (US) 2003-11-06 WO disclosed
CN-1429126-A Use of cyanoquinolines for treating or inhibiting colonic polyps AMERICAN CYANAMID CO (US) 2003-07-09 CN disclosed
US-6540793-B1 Coupler for use in oxidative hair dyeing CLAIROL INCORPORATED 2003-04-01 US disclosed